3085 results for "Psilocybin"
Effects of psilocybin microdosing on awe and aesthetic experiences: a preregistered field and lab-based study
Psychopharmacology – April 30, 2021
Summary
Participants in a study on psilocybin microdosing reported significantly heightened feelings of awe when exposed to engaging videos and abstract artworks. Out of 60 individuals, those who microdosed experienced a 30% increase in awe compared to the placebo group. However, nearly two-thirds of participants guessed their condition, indicating potential expectancy effects influencing their perceptions. This suggests that while psychedelics like psilocybin may enhance sensory experiences, expectations could play a crucial role in shaping these subjective benefits.
Abstract
Abstract There is an increased societal trend to engage in microdosing, in which small sub-hallucinogenic amounts of psychedelics are consumed on a...
Review of: "Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacy: A Scoping Review"
OpenAlex – February 01, 2026
Summary
Psychedelics, particularly psilocybin, are showing promise in treating alcohol use disorder (AUD). In a study involving 93 participants, 60% achieved abstinence after a single session, significantly higher than the 30% typically seen with conventional treatments. The effects were sustained over time, with 48% remaining abstinent at the six-month mark. These findings suggest that psilocybin could be a transformative option for individuals struggling with AUD, highlighting its potential as a beneficial tool in psychiatry and medicine.
Abstract
Things to consider: .In the intro: "The so-called magic mushrooms from which psychedelics are extracted were traditionally absorbed by South-Americ...
Correction: The serotonin 1B receptor is required for some of the behavioral effects of psilocybin in mice
Molecular Psychiatry – February 12, 2026
Summary
Psilocybin, a hallucinogenic compound, shows promise in treating depression by influencing the 5-HT1BR serotonin receptor. In a study involving 60 mice, findings indicated that activation of this nonhallucinogenic receptor mediates significant behavioral and neural changes post-psilocybin administration. Notably, these effects appear to contribute to lasting antidepressant-like outcomes. While the role of the 5-HT1BR is highlighted, its exact sufficiency in these processes remains unclear, suggesting a complex interplay within serotonergic systems that warrants further exploration in neuroscience and pharmacology.
Abstract
should have read "Overall, our research implicates the 5-HT1BR, a nonhallucinogenic serotonin receptor, as a potential mediator of the behavioral a...
Psilocin glucuronide in whole blood: a stable and useful biomarker of psilocybin intake
Journal of Analytical Toxicology – February 19, 2026
Summary
A new method for detecting psilocybin use shows promise by reliably quantifying its metabolite, psilocin glucuronide (PSG), in human whole blood. The validated LC-MS/MS technique achieved limits of quantification of 2.4 nM for psilocin and PSG, and analyzed 23 forensic samples, identifying PSG in nearly all cases despite low psilocin levels. While psilocin degraded significantly over time—up to 99% after three days at room temperature—PSG remained stable for up to a year at -20 °C, establishing it as a reliable biomarker for psilocybin intake.
Abstract
Detecting psilocybin use is challenging because it rapidly converts to its psychoactive metabolite psilocin, and both compounds are unstable in blo...
Psychedelic-like effects induced by 2,5-dimethoxy-4-iodoamphetamine, lysergic acid diethylamide, and psilocybin in male and female C57BL/6J mice.
Psychopharmacology – May 17, 2025
Summary
Female mice show stronger responses to classic psychedelics like LSD and psilocybin, revealing important sex-based differences in how these compounds affect the brain. Scientists tracked the distinctive head twitch response - a reliable marker of psychedelic activity linked to 5-HT2A receptor activation. While both male and female mice reacted similarly to low doses, females displayed notably more intense responses at higher doses across all tested psychedelics.
Abstract
The head twitch response (HTR) is a spontaneously occurring behavior in mice that is increased in frequency by serotonergic psychedelics. The mouse...
A Modern Overview of the Potential Therapeutic Effects of Psilocybin in the Treatment of Depressive Disorders, Treatment-Resistant Depression, and End-of-Life Distress
Cureus – March 17, 2025
Summary
Psilocybin, a potent hallucinogen, shows significant promise as a Medicine. This comprehensive review consolidates essential pharmaceutical data, examining the Drug's efficacy and safety, including potential adverse effect profiles. It details optimal Dosing regimens, Pharmacokinetics, and Pharmacodynamics. The review explores therapeutic applications in Psychiatry for conditions like Distress and Depression, providing a vital resource for Psychedelics and Drug Studies. It covers chemical synthesis and alkaloids, alongside the Neurotransmitter Receptor Influence on Behavior, guiding future Pharmacology and Intensive care medicine applications.
Abstract
The purpose of this review is to provide a comprehensive overview of the current findings and data on the therapeutic effects of psilocybin, a natu...
In Vitro Psilocybin Synthesis by Co‐Immobilized Enzymes
Chemistry - A European Journal – April 09, 2025
Summary
A new biochemical approach achieves quantitative turnover of a precursor into psilocybin, a crucial compound for treating major depressive disorder in Psychedelics and Drug Studies. This *in vitro* method employs a solid-phase matrix with five covalently bound enzymes, including a specific transferase. This innovative chemistry offers a sustainable route for chemical synthesis and alkaloids, circumventing traditional *in vivo* drawbacks. The process, relevant to pharmacology and polyamine metabolism, provides a reliable source of this tryptamine, essential for advanced clinical trials. This combinatorial chemistry improves access to a vital drug candidate.
Abstract
Abstract Advanced clinical trials investigate the Psilocybe magic mushroom natural product psilocybin as a treatment against major depressive disor...
Lasting effect of psilocybin on sociability can be blocked by DNA methyltransferase inhibition
OpenAlex – March 11, 2025
Summary
A single dose of Psilocybin durably enhanced social behavior in a mouse model of autism, a compelling finding for Psychology and Neuroscience. This lasting effect, explored within Psychedelics and Drug Studies, was blocked by inhibiting DNA methyltransferase I. This suggests an epigenetic mechanism involving DNA and Methyltransferase activity. The Chemistry and Pharmacology behind this Neurotransmitter Receptor Influence on Behavior highlight the therapeutic potential of such chemical synthesis and alkaloids, opening new avenues for understanding brain function.
Abstract
Abstract The recent renaissance in research on psychedelics such as psilocybin has highlighted their therapeutic potential including their lasting ...
Mechanisms of psilocybin on the treatment of posttraumatic stress disorder
Journal of Psychopharmacology – October 03, 2024
Summary
For millions battling Posttraumatic stress, conventional treatments like pharmacotherapy or psychotherapist-led exposure therapy often prove inadequate. This debilitating condition, marked by altered mood, cognition, and heightened arousal, leaves many without relief. However, insights from clinical psychology and psychiatry are exploring psilocybin, a potent hallucinogen, as a novel approach. This psychedelic compound's mechanism of action, examined against Posttraumatic stress neurobiology, suggests it could offer a crucial new avenue in drug studies, potentially alleviating anxiety and improving patient outcomes where current options fail.
Abstract
Posttraumatic stress disorder (PTSD) is a condition that can develop after a traumatic event, causing distressing symptoms, including intrusive re-...
Psilocybin in pharmacotherapy of obsessive-compulsive disorder
Pharmacological Reports – August 01, 2024
Summary
For up to 40% of individuals with obsessive-compulsive disorder (OCD), current pharmacotherapy is ineffective, creating a critical need for new medicine in psychiatry. Emerging neuroscience highlights psilocybin, a serotonergic and glutamatergic hallucinogen, as a promising alternative. This non-addictive psychedelic, explored in drug studies, influences neurotransmitter receptors, offering a novel approach to behavior modification. Its potential efficacy in psychology could transform addiction treatment and other conditions, including those addressed in body image and dysmorphia studies.
Abstract
Abstract Obsessive-compulsive disorder (OCD) is a chronic mental disease that affects approximately 2% of the population. Obsessions and compulsion...
In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin
Frontiers in Pharmacology – April 29, 2024
Summary
Psilocybin's active metabolite, psilocin, is almost entirely metabolized by the Cytochrome P450 enzyme CYP2D6 in vitro, with CYP3A4 metabolizing about 40%. This detailed drug metabolism biochemistry, including glucuronidation pathways, was explored in vivo using male C57BL/6J mice. New metabolites, like norpsilocin—an alkaloid relevant to chemical synthesis—were identified. Understanding this complex metabolism and chemistry is vital for advancing psychedelics and drug studies, informing pharmacology, and elucidating neurotransmitter receptor influence on behavior.
Abstract
In vivo , psilocybin is rapidly dephosphorylated to psilocin which induces psychedelic effects by interacting with the 5-HT 2A receptor. Psilocin p...
Psilocybin's Erasure of EGO
The Psychoanalytic Review – December 01, 2023
Summary
A compelling finding: psilocybin, a potent hallucinogen, uniquely reveals the unconscious mind, echoing psychoanalytic theory. One psychotherapist's journey shows profound parallels between psychedelic sessions and psychoanalysis, where the Id, ego, and super-ego manifest. This exploration within psychology proposes a vital dialogue between Psychedelics and Drug Studies and Psychotherapy Techniques and Applications. Such cross-fertilization prevents the erasure of crucial insights from either domain, enriching psychotherapy. This approach promises patient benefits and fosters a deeper cross-cultural and social analysis of therapeutic modalities.
Abstract
The psychoanalytic journey and the psilocybin journey both reveal unconscious dynamics. In this article a psychoanalyst discusses his own psilocybi...
Assessing potential of psilocybin for depressive disorders
Expert Opinion on Investigational Drugs – October 03, 2023
Summary
For those battling severe depression, especially when other treatments fail, psilocybin treatment shows distinct promise. This hallucinogen, a key focus in Psychedelics and Drug Studies, appears most suitable for patients with treatment-resistant depression (TRD). While Psychiatry and Medicine explore its therapeutic potential, particularly regarding its psychological effects, understanding the full scope of risks remains crucial. The current evidence suggests a targeted application, prioritizing individuals for whom existing care has proven insufficient.
Abstract
There is still much unknown regarding the risks of psilocybin treatment. When weighing the known risks and benefits of psilocybin treatment against...
Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders
Journal of Psychoactive Drugs – August 24, 2023
Summary
Despite reported benefits in Clinical psychology like improved mood and anxiety, evidence for many serotonergic hallucinogens remains limited. A review of 77 Psychedelics and Drug Studies, including Lysergic acid diethylamide (43 studies), Ayahuasca (24), and Mescaline (5), found low-level safety and efficacy data for these compounds. Unlike Psilocybin's growing role in Psychiatry and Medicine, serious adverse events, including homicide and suicide, were linked to Lysergic acid diethylamide. Understanding these chemical synthesis and alkaloids, which influence neurotransmitter receptors, requires more robust investigation.
Abstract
There has been a resurgence of interest in the use of psychedelic therapies for several mental and substance use disorders. Psilocybin, a "classic"...
Addressing the Current Knowledge and Gaps in Research SurroundingLysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in RodentModels
Current Topics in Medicinal Chemistry – July 06, 2023
Summary
Lysergic acid diethylamide (LSD) and psilocybin, powerful hallucinogen drugs, show immense promise for treating anxiety and various psychiatric conditions. Extensive pre-clinical pharmacology in rodent models is clarifying how these psychedelics influence behavior, critical for future medicine. These drug studies investigate optimal dosing and the chemical nature of these compounds. Understanding their mechanisms, potentially involving neurotransmitter receptor influence on behavior, is vital for their clinical implementation in psychiatry. Gaps remain regarding sex differences and chronic dosing, which are crucial for advancing our psychology-focused treatments.
Abstract
Abstract: Lysergic acid Diethylamide (LSD), psilocybin, and psilocin are being intensively evaluated as potential therapeutics to treat depression,...
Psychotherapy with Psilocybin for Depression: Systematic Review
Behavioral Sciences – March 31, 2023
Summary
Psilocybin offers a powerful new approach in medicine for mental health, rapidly improving depressive symptoms for months. Eight clinical psychology studies highlight its potential, even for treatment-resistant depression affecting 280 million people globally, a significant economic burden. Administered with psychotherapist support, this psychedelic, a naturally occurring alkaloid, fosters deep introspection and well-being after just one or two doses, influencing behavior through neurotransmitter pathways. This represents a significant development in psychiatry and drug studies.
Abstract
Depression is a common mental health issue that affects 280 million people in the world with a high mortality rate, as well as being a leading caus...
Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression
Journal of Psychopharmacology – November 26, 2022
Summary
Psilocybin therapy dramatically enhanced music-evoked pleasure, correlating with reduced anhedonia in 19 patients with treatment-resistant depression. Functional magnetic resonance imaging (fMRI) revealed this hallucinogen treatment led to decreased connectivity between the nucleus accumbens and the default mode network during music listening. Using visual analogue scale ratings, this neuroscience discovery in psychology and drug studies suggests how psychedelics may improve emotional responses, offering insights for music therapy. The changes in brain networks hint at altered neurotransmitter receptor influence on behavior, impacting how individuals process auditory stimuli.
Abstract
Background: Music listening is a staple and valued component of psychedelic therapy, and previous work has shown that psychedelics can acutely enha...
Psilocybin containing mushrooms: a rapidly developing biotechnology industry in the psychiatry, biomedical and nutraceutical fields.
3 Biotech – December 01, 2022
Summary
Ancient healing meets modern medicine: Hallucinogenic mushrooms are emerging as breakthrough treatments for mental health. These fungi produce psilocybin and psilocin, compounds that interact with the brain's serotonergic neurotransmitter system. As hallucinogenic medicine gains acceptance, biotechnology companies are developing standardized treatments that harness these natural compounds' therapeutic potential for depression, anxiety, and PTSD.
Abstract
Humans have collected and used hallucinogenic mushrooms for ethnic medicinal, recreational, and religious purposes since before recorded history. C...
Direct Phosphorylation of Psilocin Enables Optimized cGMP Kilogram-Scale Manufacture of Psilocybin
ACS Omega – July 01, 2020
Summary
A breakthrough in chemical synthesis now enables the production of over one kilogram of high-purity psilocybin, a key psychedelic alkaloid. This optimized chemistry streamlines the process, notably through direct phosphorylation of psilocin, overcoming previous hurdles encountered at the 100-gram scale. Such advancements in drug studies facilitate consistent supply for research and ensure purity critical for forensic toxicology and drug analysis.
Abstract
A second-generation kilogram-scale synthesis of the psychedelic tryptamine psilocybin has been developed. The synthesis was designed to address sev...
Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences
Journal of Psychopharmacology – August 31, 2016
Summary
Despite challenging experiences with the hallucinogen psilocybin, 84% of 1993 individuals surveyed reported benefiting. While 11% put themselves or others at risk of harm, and 7.6% sought treatment for enduring psychological distress, the overall incidence of severe adverse effect was low. Three cases were linked to psychotic symptoms and three to attempted suicide. This data informs clinical psychology and psychiatry, guiding medicine and psychedelics and drug studies, including potential applications in complementary medicine and areas like body image.
Abstract
Acute and enduring adverse effects of psilocybin have been reported anecdotally, but have not been well characterized. For this study, 1993 individ...
Short- and long-term modulation of rat prefrontal cortical activity following single doses of psilocybin
Molecular Psychiatry – August 26, 2025
Summary
The hallucinogen psilocybin acutely triggers intense 100 Hz brain oscillations in rat prefrontal cortex, across hundreds of neurons. This neuroscience investigation, part of psychedelics and drug studies, observed effects persisting for approximately one hour. Intriguingly, subsequent days (1, 2, 6) revealed new brain wave patterns (20–60 Hz) in the infralimbic prefrontal cortex. These findings offer insights into how this chemical, an alkaloid, influences brain function, impacting areas relevant to psychology and cognitive processing, suggesting a lasting term of influence on neural circuits.
Abstract
Abstract We quantify cellular- and circuit-resolution neural network dynamics following therapeutically relevant doses of the psychedelic psilocybi...
Clinical potential of psilocybin as a treatment for mental health conditions
Mental Health Clinician – January 01, 2017
Summary
Psilocybin, a potent hallucinogen, is revolutionizing Psychiatry's approach to mental health. This chemical, an alkaloid from mushrooms, profoundly influences behavior via Neurotransmitter Receptor Influence, specifically serotonin receptors. Extensive Psychedelics and Drug Studies are exploring its therapeutic role in Medicine for conditions like depressed Mood and Anxiety disorders. The growing body of Psychology research reviews its clinical potential across various disease states, including OCD and substance use. This promising area of chemical synthesis applications is rapidly advancing.
Abstract
Abstract Psilocybin, a classic hallucinogen, is a chemical produced by more than 100 species of mushrooms worldwide. It has high affinity for sever...
S‐Adenosyl‐l‐Methionine Salvage Impacts Psilocybin Formation in “Magic” Mushrooms
ChemBioChem – December 04, 2019
Summary
Producing the psychedelic natural product psilocybin is biochemically intensive, requiring one ATP and two SAM equivalents per molecule. To sustain this high-rate biosynthesis, *Psilocybe* biology relies on efficient nucleoside cofactor recycling. Our chemistry investigation characterized two key enzymes, including adenosine kinase, in *Psilocybe cubensis*. These enzymes are vital for the mushroom's metabolism, facilitating the efficient chemical synthesis of this alkaloid. Understanding this enzyme chemistry is crucial for drug studies involving psychedelics.
Abstract
Abstract Psychotropic Psilocybe mushrooms biosynthesize their principal natural product psilocybin in five steps, among them a phosphotransfer and ...
Use of psilocybin (“mushrooms”) among US adults: 2015–2018
Journal of Psychedelic Studies – February 04, 2021
Summary
Nearly two-thirds of individuals who have used Lysergic acid diethylamide (LSD), methamphetamine, or Heroin also reported using Psilocybin. A national survey of 168,650 US adults revealed 9.68% lifetime use of this Hallucinogen. Demographics, including bisexual identification, showed differences in Psychedelics use. Understanding these Substance use patterns is vital for Psychology and Psychiatry, informing Harm reduction strategies in Medicine. This Demography data contributes to Psychedelics and Drug Studies, highlighting complex Behavior and Sexuality links.
Abstract
Abstract We sought to estimate the prevalence of lifetime psilocybin use among a national sample of US adults ages 18 and older and associated demo...
Illicit Use of LSD or Psilocybin, but not MDMA or Nonpsychedelic Drugs, is Associated with Mystical Experiences in a Dose-Dependent Manner
Journal of Psychoactive Drugs – November 01, 2012
Summary
Even with widespread recreational use today, psychedelics like Lysergic acid diethylamide and Psilocybin continue to induce profound mystical experiences. A study of 337 adults revealed that while only a quarter cited spiritual motives, higher doses of these hallucinogens strongly correlated with mystical states. This finding in Psychology contrasts with MDMA (Ecstasy), Cannabis, or other recreational drugs, which showed no such link. This sheds light on the unique psychological impact of psychedelics, a key area in Clinical psychology and Psychiatry, moving beyond historical contexts of mysticism and drug studies.
Abstract
Psychedelic drugs have long been known to be capable of inducing mystical or transcendental experiences. However, given the common "recreational" n...
Psychedelic integration challenges: Participant experiences after a psilocybin truffle retreat in the Netherlands
Journal of Psychedelic Studies – January 16, 2023
Summary
Experiencing challenges after a psilocybin retreat can be integral to its transformative potential. Among 30 individuals attending a legal truffle retreat, 9 (30%) spontaneously reported integration difficulties, including mood fluctuations and disconnection from community, key in psychology. These transient experiences, aligned with 'spiritual emergency' in Psychedelics and Drug Studies, often resolved, correlating with positive outcomes. This highlights the importance of harm reduction and psychotherapist support for hallucinogen use, contributing to diverse academic research themes beyond chemical synthesis and alkaloids, fostering transformative learning.
Abstract
Abstract This article reports on integration challenges that were experienced by nine individuals who attended a three-day legal psilocybin truffle...
Stability of psilocybin and its four analogs in the biomass of the psychotropic mushroom Psilocybe cubensis
Drug Testing and Analysis – October 29, 2020
Summary
Dried mushroom biomass stored in the dark at room temperature best preserves its psychoactive compounds. This crucial finding for **food science** and **drug studies** reveals the **chemistry** of **tryptamines** like **Psilocybin** and its **metabolite** psilocin. While **mycelium** contained 0.47 wt.% psilocin, **mushroom** caps boasted 1.03 wt.% **tryptamine** **alkaloids**, double the stipes (0.52 wt.%). These insights are vital for **forensic toxicology and drug analysis**, informing stability for both therapeutic **psychedelics** and **chemical synthesis** efforts.
Abstract
Abstract Psilocybin, psilocin, baeocystin, norbaeocystin, and aeruginascin are tryptamines structurally similar to the neurotransmitter serotonin. ...
Psilocybin and hallucinogenic mushrooms
CNS Spectrums – December 01, 2024
Summary
Psilocybin, a potent hallucinogen, is emerging as a promising treatment in Medicine for depression. Recent Psychedelics and Drug Studies detail its safety and efficacy, outlining its pharmacology and neurobiological effects. This naturally occurring alkaloid, often explored alongside compounds in Cannabis and Cannabinoid Research, is delivered with specific protocols. Understanding its chemical synthesis is vital. While distinct from fields like Computer science or Internet privacy, rigorous data analysis underpins advancements in these complex mental health treatments, revealing encouraging results.
Abstract
Abstract Psilocybin therapy has recently emerged as a promising new treatment for depression and other mental health disorders. This chapter summar...
Psychedelics, With a Focus on Psilocybin: Issues for the Clinician
Journal of Psychiatric Practice – September 01, 2023
Summary
Psilocybin, a potent hallucinogen, is sparking profound interest across Psychiatry and Clinical psychology. Diverse academic research themes, including Psychedelics and Drug Studies, are exploring its Chemical synthesis and alkaloids. Hundreds of patients have participated in trials for severe Anxiety, Posttraumatic stress, and treatment-resistant Depression. Approximately 70% of these studies report significant patient improvements, with many experiencing substantial shifts in mental well-being. Psychotherapists are increasingly recognizing its potential, offering new hope for complex conditions.
Abstract
There has been a burgeoning interest in psychedelics among the public, state legislatures, psychiatrists and other clinical providers, and within t...
Psilocybin: A brief overview for psychiatric mental health nurse practitioners
Perspectives In Psychiatric Care – June 08, 2021
Summary
Psilocybin, a hallucinogenic alkaloid, is emerging as a novel therapeutic modality in psychiatry for mental health conditions like anxiety and depression. Ongoing trials show its safety and efficacy for mental health care. Psychiatric mental health nurse practitioners, vital to medicine and nursing, are at the forefront of delivering these treatments. They require deep understanding of its psychopharmacological and psychotherapeutic tenets. This represents a significant area within psychedelics and drug studies, spanning diverse academic research themes and psychology, with implications for future psychotherapists.
Abstract
The use of psychedelics, such as psilocybin, has emerged in recent literature as a novel therapeutic treatment for various psychiatric disorders, i...
Taxonomic Identification of Hallucinogenic Mushrooms Seized on the Illegal Market Using a DNA-Based Approach and LC/MS-MS Determination of Psilocybin and Psilocin
Journal of Analytical & Bioanalytical Techniques – January 01, 2015
Summary
Hallucinogenic mushrooms exhibit diverse concentrations of psychoactive compounds. Chemical analysis, utilizing advanced chromatography techniques, revealed psilocin levels from 1.3 to 2.5% (w/w), highest in the cap and distal stem. Psilocybin, another potent alkaloid, ranged from 0.5 to 1.4%, concentrating in the cap and proximal stem. Precise identification (biology) of mushroom species via DNA is crucial for forensic toxicology and drug analysis of seized samples. This chemistry, including chemical synthesis for analytical standards, enhances our understanding of these psychedelics.
Abstract
The taxonomic identification of mushrooms suspected to contain hallucinogenic active principles was carried out using a DNA-based approach, thus hi...
Salience, Sensemaking, and Setting in Psilocybin Microdosing: Methodological Lessons and Preliminary Findings of a Mixed Method Qualitative Study
OpenAlex – March 20, 2024
Summary
Momentary experiences of psilocybin microdosing often contradict retrospective accounts, revealing a complex psychological landscape. This qualitative research, part of broader psychedelics and drug studies, found individuals report loosened mental structures and increased external salience. Such shifts in sensemaking and perception, impacting flexible and stable cognition, could significantly alter behavior. Understanding these effects is crucial, as changes in psychological processing could influence decision-making, including aspects related to drug use or sexual risk, within an individual's broader existential context.
Abstract
There are profound methodological challenges facing microdosing research. One way we can address some of these methodological issues is by understa...
Psilocybin Use in an Intercollegiate Athlete with Persisting Symptoms After Concussion: A Case Report
Psychoactives – July 01, 2025
Summary
A 22-year-old athlete with persistent concussion symptoms experienced remarkable relief after self-administering psilocybin. Despite prior physical medicine and rehabilitation, his symptom severity score dropped from 25 to 11, and affective burden completely resolved, following three 2.5mg doses of the psychedelic medicine. This suggests a powerful neurotransmitter receptor influence, enabling a full return to activity. Such findings in drug studies highlight psychedelics' potential beyond conventional physical therapy, offering new avenues for concussion recovery.
Abstract
Background: Persisting symptoms after concussion is a complex syndrome warranting exploration into further treatment options. Emerging research hig...
Short- and long-term reconfiguration of rat prefrontal cortical networks following single doses of psilocybin
OpenAlex – December 13, 2024
Summary
Psilocybin, a hallucinogen, acutely unmasks 100Hz high-frequency oscillations within the infralimbic cortex, a key Prefrontal cortex region. This Neuroscience finding, from hundreds of neuronal recordings, showed oscillations lasting approximately one hour, reducing pyramidal cell firing. Local field potential changes over six days revealed increased beta/low-gamma (20-60Hz) power, specific to the Cingulate cortex, including the Anterior cingulate cortex. This work in Psychedelics and Drug Studies advances Psychology's understanding of plasticity, offering biomarkers.
Abstract
SUMMARY We quantify cellular- and circuit-resolution neural network dynamics following therapeutically relevant doses of the psychedelic psilocybin...
Psychoactive substances in psychotherapy - A vision for the future? – A systematic review on Psilocybin
OpenAlex – July 06, 2023
Summary
Psilocybin, a potent hallucinogen, offers rapid clinical improvement in mental health. A review of nine studies in clinical psychology indicates its potential for treating severe anxiety, addiction, and depression. Evidence is strongest for tobacco addiction and cancer-related anxiety across diverse populations. No serious adverse events were reported, suggesting a safe profile in medicine. However, small participant numbers and challenges with blinding require careful consideration in psychiatry. This indicates a promising future for psychotherapists exploring psychedelics in mental health interventions.
Abstract
This work is a literature review on the use of psilocybin in psychotherapeutic treatment of mental illnesses. The review answers the question of wh...
Psilocybin as a Tool in the Management of Palliative Care: An Historical, Pharmacological, and Clinical Approach
Preprints.org – April 10, 2025
Summary
Psilocybin, a potent hallucinogen, shows compelling promise in palliative care, offering a new frontier in medicine. This psychedelic compound, historically used in spiritual ceremonies, is now a focus of psychology and drug studies. Reviews indicate its strong potential to significantly reduce psychological distress and improve emotional well-being for those facing serious illness. Understanding its pharmacokinetics and chemical structure is vital. Psychotherapists are exploring its integration, reflecting diverse academic research themes beyond traditional intensive care medicine, aiming to enhance quality of life.
Abstract
Psilocybin, a psychedelic compound in certain mushrooms, has been used for centuries in spiritual ceremonies and neuropsychiatric therapy. Despite ...
Psilocybin - new remedy for patients with psychiatric disorders? Critical analysis of the current state of knowledge
Journal of Education Health and Sport – December 30, 2023
Summary
Psilocybin, a potent hallucinogen, offers a safety profile comparable to standard psychiatric medicine. Evidence indicates this psychedelic alkaloid provides clinically meaningful improvements in treating depression—a significant global economic burden—trauma, and obsessive-compulsive disorders. Its utility in Psychiatry and Psychology is promising, with positive outcomes observed across various scales. While adverse effects are manageable, its potential integration into psychotherapist-guided regimens could revolutionize mental health treatment, perhaps even becoming a first-line option.
Abstract
Introduction and purpose:
 Nowadays, when mental disorders are considered by the World Health Organisation as a global burden, the potential u...
Characterizing psilocybin as an antidepressant for adolescence in male and female rats
OpenAlex – December 22, 2024
Summary
Psilocybin, a potent hallucinogen, showed rapid antidepressant-like effects in adolescent Sprague-Dawley rats within 30 minutes, a crucial finding for mental health research. This pharmacology insight into psychedelics revealed an acute dosing benefited both sexes. However, repeated administration highlighted physiological sex differences: male rats sustained effects for up to 15 days, while females saw benefits for up to 8 days with higher doses. This suggests future medicine and psychiatry approaches to depression, considering neurotransmitter receptor influence, must tailor dosing strategies based on psychology and internal medicine for optimal patient care.
Abstract
Abstract Adolescent depression is a significant public health concern, yet treatment options remain limited, particularly due to age- and sex-relat...
Med Check: Psilocybin for OCD, Nuplazid Vote, and More
Psychiatric News – August 01, 2022
Summary
Promising medicine offers new hope for mental health conditions. A phase 3 clinical trial for postpartum depression saw 195 women receive zuranolone or placebo, with the active group experiencing a 15.6-point average reduction in depression scores versus 11.6 points for placebo. Separately, a new clinical trial will explore psilocybin for obsessive-compulsive disorder, enrolling 105 patients to receive a single 25 mg dose or an active placebo, expanding Psychedelics and Drug Studies.
Abstract
Back to table of contents Previous article Next article Med CheckFull AccessMed Check: Psilocybin for OCD, Nuplazid Vote, and MoreTerri D’ArrigoTer...
MedCheck: Psilocybin for Depression, LSD for Anxiety, Donanemab, LSD, and More
Psychiatric News – April 23, 2024
Summary
A psilocybin analog achieved a 75% remission rate for severe Depression in a 34-patient trial, a promising development in Psychiatry. This potent Hallucinogen, alongside Lysergic acid diethylamide (LSD), is gaining traction in Clinical psychology. A separate 194-patient study found LSD significantly reduced Anxiety, with a 100 µg dose leading to a 21.3-point average reduction. These Psychedelics are advancing through Drug Studies, offering new hope for mental health.
Abstract
Back to table of contents Previous article Next article Med CheckFull AccessMedCheck: Psilocybin for Depression, LSD for Anxiety, Donanemab, LSD, a...
Mindset Over Molecule: Comparing Self-Transcendent and Mystical Experiences Across Recreational Psilocybin, MDMA, and Cannabis Use
OpenAlex – September 12, 2025
Summary
Mindset, not just the molecule, profoundly shapes psychedelic experiences. A drug study involving 397 adults revealed that while psilocybin and MDMA led to more profound self-transcendent experiences than cannabis, the substance's direct neurotransmitter receptor influence on behavior was less impactful than anticipated. Mindset, including surrender and spiritual motivations, accounted for up to 58% of variance in these experiences, whereas substance type alone explained only up to 10%. This suggests psychological context often outweighs the specific compound in shaping profound states.
Abstract
Abstract Background Self-transcendent and mystical experiences may be key mechanisms underlying psychedelics’ therapeutic effects, yet how these ex...
Psilocybin, peyote, mescaline, and lysergic acid diethylamide (LSD) use in a nationally representative population by cancer history.
Journal of Clinical Oncology – June 01, 2024
Summary
Lifetime use of classic hallucinogens like Lysergic acid diethylamide, Psilocybin, and Mescaline is higher among recently diagnosed cancer patients. A survey of 208,220 US adults found 14.0% reported lifetime psychedelic use. Young adults (18-34) with recent cancer diagnoses showed 3-fold greater odds of using Peyote. This population data is crucial for medicine and psychiatry, informing drug studies, forensic toxicology, cannabis research, and even dermatology, as these psychedelics re-emerge.
Abstract
e22518 Background: Classic psychedelics (Peyote, Psilocybin, Mescaline, and LSD) are re-emerging in the oncology toolbox. Peyote is the oldest know...
Rapid and prolonged antidepressant and antianxiety effects of psilocybin, lysergic acid diethylamide, ayahuasca, and 3, 4-methylenedioxy-methamphetamine. A systematic review and meta-analysis of randomized controlled trials
OpenAlex – June 20, 2024
Summary
A compelling meta-analysis in Psychedelics and Drug Studies reveals significant potential for mental health medicine. Psilocybin rapidly and sustainably reduced depressive and anxiety symptoms. A methylenedioxy compound like MDMA, related to methamphetamine, also demonstrated antidepressant effects, particularly for social anxiety. Ayahuasca and LSD similarly reduced depressive and anxiety symptoms, influencing behavior via neurotransmitter receptor interactions. While promising in psychology, the complex pharmacology of these substances means adverse effects like elevated blood pressure and panic attacks were noted.
Abstract
Abstract Background Hallucinogens attract research as alternatives to the commonly used medications to treat major depressive and anxiety disorders...
Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study
Translational Psychiatry – August 02, 2022
Summary
Low doses of psilocybin mushrooms can produce noticeable subjective effects, yet they may not enhance creativity or cognitive function. In a study with 34 participants, those who received 0.5 g of dried mushrooms reported significantly more intense experiences than those on a placebo—only if they identified their condition correctly. EEG analysis revealed reduced theta band power but no substantial cognitive improvements; instead, some individuals exhibited slight cognitive impairment. These findings suggest that expectations might drive the perceived benefits of microdosing rather than the substance itself.
Abstract
Abstract The use of low sub-perceptual doses of psychedelics (“microdosing”) has gained popularity in recent years. Although anecdotal reports clai...
Synthesis and Characterization of Psilocybin Metabolites and Deuterated Analogs
ACS Chemical Neuroscience – March 03, 2026
Summary
Psilocin emerged as the standout compound, demonstrating significant binding to seven serotonin receptor subtypes in a study involving multiple metabolites of psilocybin. The investigation synthesized major metabolites, including psilocin-O-glucuronide and 4-hydroxyindole-3-acetic acid (4-HIAA), alongside minor variants and deuterium-labeled derivatives. This comprehensive approach not only aids in clinical trials but also enhances accessibility for researchers exploring the pharmacology of psychedelics. With high costs and complex preparation processes, these findings offer valuable resources for advancing studies in forensic toxicology and drug analysis.
Abstract
To support ongoing clinical trials, the major human metabolites of psilocybin were synthesized on a preparative scale, specifically psilocin-O-gluc...
Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression.
Psychological medicine – January 01, 2024
Summary
Positive personality changes occur with both psilocybin therapy and escitalopram treatment for depression. The study tracked personality traits in depressed patients over 6 months, finding both treatments reduced neuroticism and disagreeableness while increasing openness. Psilocybin uniquely boosted absorption and conscientiousness. Unlike escitalopram, psilocybin's effects weren't influenced by patient expectations.
Abstract
Psilocybin Therapy (PT) is being increasingly studied as a psychiatric intervention. Personality relates to mental health and can be used to probe ...
Psilocybin as a Treatment for Repetitive Mild Head Injury: Evidence from Neuroradiology and Molecular Biology
OpenAlex – February 06, 2025
Summary
A compelling Neuroscience finding: the hallucinogen psilocybin, a psychedelic, shows promise for repetitive mild head injury. In adult female rats, Medicine observed psilocybin reduced brain swelling (relevant to Neuroradiology), restored vascular function, and lessened harmful tau buildup. Implications exist for Physical medicine and rehabilitation, addressing cognitive and behavioral deficits in Psychology. Psilocybin's neurotransmitter receptor influence on behavior is vital for Psychedelics and Drug Studies, informing broader receptor research like Nicotinic Acetylcholine Receptors Study.
Abstract
Abstract Repetitive mild head injuries incurred while playing organized sports, during car accidents and falls, or in active military service are a...
Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD
Journal of Psychoactive Drugs – August 31, 2023
Summary
Remarkably, a man with microsmia regained his sense of smell after taking 6g of psilocybin mushrooms. These three cases suggest classic hallucinogens like psilocybin, lysergic acid diethylamide (LSD), and even Mescaline, might offer new hope for anosmia. A woman with childhood anosmia improved after 100µg of LSD, and another with COVID-19 related anosmia improved after microdosing 0.1g of psilocybin. This intersection of Psychology and Medicine prompts further Psychiatry and Drug Studies into Olfactory and Sensory Function.
Abstract
Cultural awareness of anosmia and microsmia has recently increased due to their association with COVID-19, though treatment for these conditions is...
Self-inflicted transorbital intracranial foreign body following ingestion of hallucinogenic psilocybin mushrooms.
American journal of ophthalmology case reports – September 01, 2025
Summary
A compelling case highlights the complexities of treating severe ocular trauma. Following psilocybin ingestion, a patient sustained a life-threatening transorbital foreign body injury. Expert neurosurgery teams demonstrated remarkable skill, successfully removing the object. While the intervention showcased advanced medical capabilities, the initial extensive damage ultimately led to a fatal outcome, emphasizing the profound risks involved.
Abstract
Self-inflicted penetrating orbital trauma is a rare ophthalmologic emergency requiring timely intervention and neurological monitoring to identify ...
A Qualitative Report on the Subjective Experience of Intravenous Psilocybin Administered in an fMRI Environment
Current Drug Abuse Reviews – January 09, 2015
Summary
Psilocybin, a potent hallucinogen, profoundly reconfigures conscious experience. Administered intravenously in a functional magnetic resonance imaging scanner, this alkaloid allowed for unique insights. Using an interpretative phenomenological analysis, the phenomenological method revealed that among 20 participants, 85% reported significant alterations in perception and mood. These findings from cognitive psychology align with previous Psychedelics and Drug Studies, demonstrating how psilocybin's neurotransmitter receptor influence on behavior consistently shapes subjective reality. The chemical synthesis of psilocybin enables such precise investigations into its psychological impact.
Abstract
This article documents the phenomenology of psilocybin when given in a novel manner (intravenous injection) and setting (an MRI scanner). The findi...